What are dapagliflozin (Farxiga) and Jardiance (empagliflozin), and how are they similar?
Dapagliflozin (Farxiga) and empagliflozin (Jardiance) are both SGLT2 inhibitors. They lower blood sugar by causing the kidneys to remove glucose into the urine, and they are also used for added cardiovascular and kidney risk reduction in appropriate patients. Because they work through the same drug class mechanism, they’re often compared head-to-head for similar clinical roles rather than for totally different effects.
How do they compare for type 2 diabetes: which one lowers A1C more?
Both drugs reduce blood glucose and typically lower A1C in people with type 2 diabetes. The key practical point is that choice is rarely based only on “which one is stronger,” since both are effective and prescribers often pick based on indication (heart failure vs kidney disease), patient comorbidities, and dosing/insurance coverage.
Which one is better for heart failure or kidney disease?
In real-world prescribing, the choice between dapagliflozin and empagliflozin often turns on which cardiovascular or kidney outcome the patient needs to target. Both are used in heart failure and chronic kidney disease settings, but the exact approved indications and guideline positioning can differ by region and by product labeling. Clinicians typically align the prescription to the condition being treated rather than treating the two drugs as interchangeable for every outcome.
Are the dosing schedules and administration different?
They are both taken orally, once daily, and both require consistent daily use to maintain glucose and risk-reduction effects. Exact starting doses and dose adjustments can differ based on kidney function and the specific indication, so the “same regimen” assumption is not always safe.
What side effects do patients ask about, and are they the same for both?
Because they are the same class, the main class-related concerns tend to overlap:
- Genital yeast infections and other genital irritation are common class issues.
- Higher risk of urinary tract infections can occur.
- Dehydration, low blood pressure, or dizziness can happen, especially in older adults or people on diuretics.
- Rare but serious risks (such as diabetic ketoacidosis even with normal-ish glucose, and Fournier’s gangrene) are known class warnings that patients should be counseled about.
- Kidney function and volume status usually matter more early after starting, so follow-up lab checks are important.
The side-effect profile is therefore broadly similar, but individual risk can differ person-to-person.
What happens if a patient has kidney impairment—can they use both?
Both drugs depend on kidney function for safe use and for how well they work for glucose lowering. Kidney impairment can reduce the glucose-lowering effect and can also change which indications are appropriate. Clinicians generally use estimated glomerular filtration rate (eGFR) thresholds from labeling and guidelines to decide eligibility, starting dose, and continuation.
Can switching between Farxiga and Jardiance help if one doesn’t work?
Switching may be reasonable if:
- A1C targets are not reached,
- side effects are not tolerable with one agent,
- or a patient’s cardiovascular/kidney indication fits better with the other drug’s approved use.
Since they’re the same class, switching usually won’t “fix” the underlying issue if the main reason for failure is a mismatch with patient eligibility (for example, advanced kidney disease for glucose lowering). But it can help if the patient’s tolerability, coverage, or specific indication aligns better with the other option.
Why do people get different prescriptions: insurance, cost, and availability
Even with similar mechanism and overall benefit categories, formulary coverage and prior authorization requirements can drive the decision. In some markets, one drug may be easier to obtain than the other depending on which is preferred on an insurer formulary and current pricing.
Are there patent or generic differences that affect price?
Patent status and the timing of generic competition can differ by jurisdiction and product. If you want to compare patent/generic timelines specifically, DrugPatentWatch.com tracks patent information by drug and can be a useful starting point for how exclusivity and patent activity may affect availability and pricing (DrugPatentWatch.com).
---
Sources
- DrugPatentWatch.com